These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30777408)

  • 21. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
    Antzelevitch C; Sun ZQ; Zhang ZQ; Yan GX
    J Am Coll Cardiol; 1996 Dec; 28(7):1836-48. PubMed ID: 8962574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome.
    Shimizu W; Antzelevitch C
    Circulation; 2000 Aug; 102(6):706-12. PubMed ID: 10931813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Noninvasive cardiac activation imaging of ventricular arrhythmias during drug-induced QT prolongation in the rabbit heart.
    Han C; Pogwizd SM; Killingsworth CR; Zhou Z; He B
    Heart Rhythm; 2013 Oct; 10(10):1509-15. PubMed ID: 23773986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cellular basis for long QT, transmural dispersion of repolarization, and torsade de pointes in the long QT syndrome.
    Shimizu W; Antzelevitch C
    J Electrocardiol; 1999; 32 Suppl():177-84. PubMed ID: 10688323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation.
    Di Diego JM; Belardinelli L; Antzelevitch C
    Circulation; 2003 Aug; 108(8):1027-33. PubMed ID: 12912819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome.
    van Opstal JM; Schoenmakers M; Verduyn SC; de Groot SH; Leunissen JD; van Der Hulst FF; Molenschot MM; Wellens HJ; Vos MA
    Circulation; 2001 Nov; 104(22):2722-7. PubMed ID: 11723026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome.
    Shimizu W; Antzelevitch C
    J Am Coll Cardiol; 2000 Mar; 35(3):778-86. PubMed ID: 10716483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Electro-mechanical (dys-)function in long QT syndrome type 1.
    Ziupa D; Menza M; Koppermann S; Moss R; Beck J; Franke G; Perez Feliz S; Brunner M; Mayer S; Bugger H; Koren G; Zehender M; Jung BA; Seemann G; Foell D; Bode C; Odening KE
    Int J Cardiol; 2019 Jan; 274():144-151. PubMed ID: 30017522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes?
    Medina-Ravell VA; Lankipalli RS; Yan GX; Antzelevitch C; Medina-Malpica NA; Medina-Malpica OA; Droogan C; Kowey PR
    Circulation; 2003 Feb; 107(5):740-6. PubMed ID: 12578878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new preclinical biomarker for risk of Torsades de Pointes: drug-induced reduction of the cardiac electromechanical window.
    Vargas HM
    Br J Pharmacol; 2010 Dec; 161(7):1441-3. PubMed ID: 20698854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ryanodine-receptor inhibition by dantrolene effectively suppresses ventricular arrhythmias in an ex vivo model of long-QT syndrome.
    Frommeyer G; Krawczyk J; Ellermann C; Bögeholz N; Kochhäuser S; Dechering DG; Fehr M; Eckardt L
    J Cardiovasc Electrophysiol; 2018 Mar; 29(3):471-476. PubMed ID: 29314443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ventricular repolarization and heart rate responses during cardiovascular autonomic function testing in LQT1 subtype of long QT syndrome.
    Haapalahti P; Viitasalo M; Perhonen M; Mäkijärvi M; Väänänen H; Oikarinen L; Hekkala AM; Salorinne Y; Swan H; Toivonen L
    Pacing Clin Electrophysiol; 2006 Oct; 29(10):1122-9. PubMed ID: 17038145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atrial-specific drug AVE0118 is free of torsades de pointes in anesthetized dogs with chronic complete atrioventricular block.
    Oros A; Volders PG; Beekman JD; van der Nagel T; Vos MA
    Heart Rhythm; 2006 Nov; 3(11):1339-45. PubMed ID: 17074641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Further observations to elucidate the role of interventricular dispersion of repolarization and early afterdepolarizations in the genesis of acquired torsade de pointes arrhythmias: a comparison between almokalant and d-sotalol using the dog as its own control.
    Verduyn SC; Vos MA; van der Zande J; Kulcsàr A; Wellens HJ
    J Am Coll Cardiol; 1997 Nov; 30(6):1575-84. PubMed ID: 9362418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes.
    Wu Y; Carlsson L; Liu T; Kowey PR; Yan GX
    J Cardiovasc Electrophysiol; 2005 Aug; 16(8):898-904. PubMed ID: 16101634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exercise worsening of electromechanical disturbances: A predictor of arrhythmia in long QT syndrome.
    Charisopoulou D; Koulaouzidis G; Rydberg A; Michael HY
    Clin Cardiol; 2019 Feb; 42(2):235-240. PubMed ID: 30537240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes.
    Antzelevitch C
    Heart Rhythm; 2005 Nov; 2(2 Suppl):S9-15. PubMed ID: 16253930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ventricular monophasic action potential changes associated with neurogenic T wave abnormalities and isoproterenol administration in dogs.
    Kuo CS; Surawicz B
    Am J Cardiol; 1976 Aug; 38(2):170-7. PubMed ID: 952261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
    Sicouri S; Antzelevitch D; Heilmann C; Antzelevitch C
    J Cardiovasc Electrophysiol; 1997 Nov; 8(11):1280-90. PubMed ID: 9395171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiarrhythmic and cardiac electrophysiological effects of SZV-270, a novel compound with combined Class I/B and Class III effects, in rabbits and dogs.
    Varga RS; Hornyik T; Husti Z; Kohajda Z; Krajsovszky G; Nagy N; Jost N; Virág L; Tálosi L; Mátyus P; Varró A; Baczkó I
    Can J Physiol Pharmacol; 2021 Jan; 99(1):89-101. PubMed ID: 32970956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.